Ads
related to: blood tests for multiple myeloma- Phase 3 Trial
Explore the Phase 3 Trial Design,
Results, and Patient Population
- Contact a Representative
For Questions and Information
About This Treatment
- Primary and Subgroup Data
Primary- and Subgroup-
Specific Data
- Patient Profile
Potential Treatment Candidates
HCPs, See Who May Be Appropriate
- Phase 3 Trial
Search results
Results from the WOW.Com Content Network
Multiple myeloma is diagnosed based on blood or urine tests finding abnormal antibody proteins (often using electrophoretic techniques revealing the presence of a monoclonal spike in the results, termed an m-spike), bone marrow biopsy finding cancerous plasma cells, and medical imaging finding bone lesions. [6]
Free light chains (FLCs) are immunoglobulin light chains that are found in the serum (blood) in an unbound (free) state. In recent decades, measuring the amount of free light chains (FLCs) in the blood has become a practical clinical test. FLC tests can be used to diagnose and monitor diseases like multiple myeloma and amyloidosis.
Monoclonal gammopathy of undetermined significance (MGUS) is a plasma cell dyscrasia in which plasma cells or other types of antibody-producing cells secrete a myeloma protein, i.e. an abnormal antibody, into the blood; this abnormal protein is usually found during standard laboratory blood or urine tests. MGUS resembles multiple myeloma and ...
As with most blood tests, false-negatives can happen, meaning results could come back negative when a cancer does exist — although Grail reports that negative cancer test results from Galleri ...
Serum protein electrophoresis (SPEP or SPE) is a laboratory test that examines specific proteins in the blood called globulins. [1] The most common indications for a serum protein electrophoresis test are to diagnose or monitor multiple myeloma , a monoclonal gammopathy of uncertain significance (MGUS), or further investigate a discrepancy ...
More recently, serum free light chain assays have been utilised in a number of published studies which have indicated superiority over the urine tests, particularly for patients producing low levels of monoclonal free light chains, as seen in nonsecretory multiple myeloma [5] [6] [7] and amyloid light chain amyloidosis (AL amyloidosis). [7] [8 ...
Ads
related to: blood tests for multiple myeloma